Fertility
World’s first live birth using eggs matured outside the body successful
In a world first, a live human birth that used an ovarian support cell (OSC) technology that matures eggs outside the body has been successful.
Unlike traditional IVF methods, which rely on 10 to 14 days of high-dose hormonal stimulation to mature eggs, this new method – named Fertilo – uses engineered, young ovarian support cells to recreate the natural egg maturation process in a laboratory setting.
This process replaces 80 per cent of hormone injections required with traditional IVF, and reduces the duration of treatment cycles to just three days, offering patients a more comfortable and less invasive experience.
This is also the first demonstration of an end-to-end process by which a therapy developed from induced pluripotent stem cells (iPSC) has the potential to improve IVF outcomes and advance women’s health.
Co-culturing immature eggs with OSCs has shown promising results to date, with the potential for higher rates of egg maturation and embryo formation.
“We are delighted to celebrate the world’s first live birth conceived using Fertilo,” said Dr. Dina Radenkovic, CEO and co-founder of Gameto which has developed the technology.
“By overcoming the major challenges of conventional IVF, such as long treatment cycles, significant side effects, and the emotional and physical strain, Fertilo provides a potentially faster, safer, and more accessible solution for families.
“This milestone marks a turning point in reproductive health and highlights the first application of iPSC technology in IVF and the immense potential of our technology.”
“This breakthrough represents a historic milestone in reproductive medicine,” said Dr. Luis Guzmán, lead at Pranor Labs & Science, who oversaw the Fertilo-enabled IVF cycle that enabled the first live birth.
“The ability to mature eggs outside the body with minimal hormonal intervention significantly reduces risks such as ovarian hyperstimulation syndrome and alleviates the side effects caused by high hormone doses.
“Fertilo is a major advancement for women who cannot tolerate or do not want to undergo the burden of the traditional IVF protocol, bringing hope and new possibilities to a broader patient population.”
“The Fertilo method was the preferred option compared to traditional approaches. With fewer injections and a gentler, less invasive egg retrieval process, it gave me hope and reassurance during a deeply personal journey,” said the mother of the first baby born through Fertilo.
“Fertilo’s innovative approach made the physical experience easier and also lightened the emotional burden of many hormone injections. I am profoundly grateful to the Pranor Clinic and the Gameto team for their care and dedication in making my dream of having a family a reality.”
Insight
Covid vaccine not linked to decrease in childbirth, study finds
Insight
Parents sue IVF clinic after delivering someone else’s baby
A Florida couple have sued an IVF clinic after giving birth to a baby who is not genetically related to either of them.
Tiffany Score and Steven Mills hired IVF Life, which operates as the Fertility Center of Orlando in Longwood to help them conceive about five years ago using in vitro fertilisation.
The couple had an embryo implanted in April and welcomed a baby girl nine months later, but soon suspected the clinic had made an error.
Both Score and Mills are white, but the baby had the appearance of a racially non-Caucasian child, according to the lawsuit.
Genetic testing confirmed that the baby is not biologically theirs. The couple filed the lawsuit on 22 January after allegedly trying to contact the clinic multiple times without getting a response.
Jack Scarola, one of the couple’s lawyers, told the Orlando Sentinel: “They have fallen in love with this child. They would be thrilled in the knowledge that they could raise this child.
“But their concern is that this is someone else’s child, and someone could show up at any time and claim the baby and take that baby away from them.”
Score and Mills are also concerned that one of the three fertilised eggs they had frozen at the clinic may have been mistakenly implanted into someone else.
They have demanded that the clinic share what happened with all other patients who had embryos stored at the facility during the year before Score gave birth. They also want IVF Life to pay for genetic testing of every child born as a result of its services over the last five years, and to account for their remaining embryos.
The couple said in a statement: “We love our little girl. We would hope to be able to continue to raise her ourselves with confidence that she won’t be taken away from us.
“At the same time, we are aware that we have a moral obligation to find and notify her biological parents, as it is in her best interest that her genetic parents are provided the option to raise her as their own.”
A family spokesperson said: “Based upon leads discovered to date, and despite the lack of help or cooperation from the clinic, there is hope that we will be able to introduce our daughter to her genetic parents and to find our own genetic child soon.”
The lawsuit names IVF Life LLC and Dr Milton McNichol, who runs the clinic.
The Fertility Center of Orlando had posted a notice on its website stating it is “actively cooperating with an investigation to support one of our patients in determining the source of an error that resulted in the birth of a child who is not genetically related to them.”
The notice was removed after a court hearing on Wednesday.
During the hearing, the judge ordered the clinic to submit a thorough plan for handling the situation by Friday.
McNichol was reprimanded by Florida’s Board of Medicine in May 2024 after an inspection of the clinic in June 2023 revealed several issues, including equipment that did not meet current performance standards, failure to comply with a risk-management plan and missing medication.
He was fined US$5,000.
Fertility
Femtech World Awards to celebrate breakthrough fertility innovations
Fertility innovation is to set to take centre stage at Femtech World’s third annual awards event.
The Femtech World Awards will celebrate some of the best examples of leadership, innovation and impact in key areas that affect women’s health and wellbeing.
The Fertility Innovation of the Year award celebrates a pioneering product, service or initiative that is transforming fertility care and support.
The winner will have demonstrated exceptional innovation in helping individuals or couples navigate fertility journeys, whether through technology, treatments, education, accessibility, or emotional support.
Consideration will be given to scientific advancement, inclusivity, user impact and the ability to break barriers in fertility health.
The award is sponsored by FinDBest IVF – a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
Launched in 2024, the platform addresses a long-standing challenge in the MedTech sector—fragmented, costly, and inefficient market access—by offering a curated, country-specific directory of active partners, complete with key segmentation, certification indicators, and direct contact tools.
From consumables and lab equipment to AI-powered embryo selection and genetic testing solutions, FinDBest makes it faster and easier for companies to scale internationally—without relying on expensive congresses or cold outreach.
Juan A. Jiménez is founder and CEO of FinDBest IVF.
He said: “As part of its commitment to driving smarter access to reproductive innovation, FinDBest IVF is proudly supporting the Femtech World Fertility Innovation Awards for the second year in a row.
“This collaboration reflects two core beliefs at the heart of the platform.
“First, FinDBest IVF was created to accelerate not only the discovery of innovative fertility solutions but their global adoption.
“By supporting these awards, the platform helps amplify breakthrough technologies—from AI-based egg quality tools to next-gen IVF microdevices—and ensures they can reach the right partners and clinics faster.
“Second, the Awards align with FinDBest’s vision of building a 360-degree commercialisation ecosystem, where innovation is not just recognised, but connected to real-world opportunities.
“Many award nominees are pioneering startups and clinical researchers—exactly the kind of innovators who benefit from FinDBest’s support in navigating regulatory complexity, distributor validation, and go-to-market strategies across diverse regions.
“Together with Femtech World, FinDBest IVF is helping to spotlight, support, and scale the future of fertility care.”
Find out more about the Femtech World Awards and enter for free here.
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Fertility4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight2 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Insight4 weeks agoInside the first wave of speakers confirmed for Women’s Health Week USA 2026





